Advanced Human Imaging Limited. - AHI STOCK NEWS

Advanced Health Intelligence Ltd (AHI) (ASX: AHI) (NASDAQ: AHI) has entered a Collaboration Agreement with UAE-Based IntelliGen FZ-LLC to deploy the AHI technology throughout the Middle East. IntelliGen will receive up to 2,000,000 AHI shares for the delivery of a USD$20,000,000 License to AHI within the region. Dr. Zaher, Co-Founder of IntelliGen, led the development of the COVID-19 vaccine research and protocol for the UAE, and is involved in the execution of multiple Saudi strategies as part of the Kingdom's 2030 vision.

Advanced Health Intelligence (AHI) has executed a binding exclusive license agreement with Changlin Network Technology Ltd, a Shanghai-based company. The agreement includes an upfront payment of $10 million to AHI, an annual license fee of $5 million, and a 25% revenue share of gross sales. Changlin plans to target an IPO in 2024 and will issue an initial 50% holding to AHI. The collaboration aims to bring AHI's innovative digital healthcare solutions to China, aligning with the country's healthcare transformation initiatives. AHI expects the initial commercial benefit to be the $10 million license fee payment within 90 days. The agreement provides AHI with opportunities for growth and expansion in the Chinese market.

Advanced Health Intelligence Ltd (AHI) has announced expanded partner opportunities in the UAE and the commencement of a joint study with Stellenbosch University. AHI has also entered US FDA submissions and cleared NASDAQ compliance requirements. The company received a $5 million placement completed at a market premium and significantly reduced its debt. AHI reported a revenue of $241,542 for the quarter ending 30 June 2023 and consolidated post-acquisition operating costs by $4.8 million per annum. There has been a strong uplift in NASDAQ trading. AHI is actively engaging in constructive dialogues to explore collaboration opportunities with various organizations within the healthcare technology industry.

Advanced Health Intelligence (ASX: AHI, NASDAQ: AHI) provides an update on their smartphone-based biometric health assessment (BHA) and their collaboration with Stellenbosch University. The study aims to validate the effectiveness of the BHA, which captures 61 health outputs and 41 biometric captures across five health categories. The initial phase of the study showed promising results, with 18 out of 20 subjects showing clinical relevance. AHI has also made an initial submission to the FDA for the categorization of their BodyScan device for obesity identification and tracking.

Advanced Health Intelligence Ltd (ASX/NASDAQ:AHI) announces a ratio change of its ADSs to ordinary shares, effective June 30, 2023. The new ratio is 1 ADS representing 28 ordinary shares. The ADS price is expected to increase proportionally.

Advanced Human Imaging Ltd (ASX, NASDAQ: AHI) has completed a Master Services Agreement with South Africa-based VERTICA Pty Ltd. This agreement allows Vertica to use AHI’s Software Development Kits (SDKs) for body circumference and face scan measurements, enhancing their digital health platform. The MSA includes service and technology support, but the financial impact on AHI is currently unquantifiable, as no minimum orders are set. AHI expects no immediate financial return, with revenue identifiable only after the commercial release of the integrated application.

Advanced Human Imaging Limited (ASX, NASDAQ: AHI) has finalized a Master Services Agreement (MSA) with Singapore's BIZBAZ Pte Ltd. This arrangement permits BizBaz to utilize AHI's Software Development Kits for body and face measurements within their application. The MSA is set for an initial term of one year, with automatic renewals. While the financial implications are currently unquantifiable, there are no minimum order commitments. AHI will provide technology support and training under this agreement, but integration timelines depend on BizBaz's technical readiness.

Advanced Human Imaging (ASX: AHI) has signed a Master Services Agreement with NEXTMEDICALL S.A.C, allowing the integration of AHI's MultiScan SDK into Nextmedicall's platform. This partnership aims to enhance telemedicine services in Latin America, providing users with tools to assess health risks and vital signs. The MSA covers essential aspects including software development, technology support, and data processing. Nextmedicall specializes in connecting chronic disease patients with healthcare providers, creating a comprehensive digital health solution.

Advanced Human Imaging Limited (ASX: AHI) announced a letter to shareholders from new CEO Dr. Katherine Iscoe, emphasizing a commitment to driving growth and innovation. She outlined plans to enhance AHI's technology, strengthen customer engagement, and improve revenue strategies. Acknowledging challenges such as a low share price, Iscoe aims to align her leadership with shareholder interests, aiming for transformative advancements in health tech using smartphone capabilities. Under her guidance, AHI seeks to expand its presence in various sectors, including health and fitness.